China SXT Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.7M
- Price
- $2.83
- % Change (Daily % change from the live per-ticker quote feed.)
- +126.40%
- Volume
- 146.6M
About
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
Quick stats
Shares outstanding1.3M
Computed float21.5K
Float / shares1.6%
Cash runway (months)124.3
Key info
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001723980
Websitehttp://www.sxtchina.com
AI Summary
AI-generated1/4
majorbearishreverse split
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
China SXT Pharmaceuticals announced a 1-for-80 consolidation of its Class A and Class B ordinary shares, effective August 10, 2026.
The reverse split will reduce the number of outstanding Class A shares from approximately 105.7 million to about 1.3 million, with fractional shares rounded up.
Shares are expected to begin trading on a post-consolidation basis on Nasdaq under the symbol 'SXTC' on August 10 with a new CUSIP number.
Red flags
- Reverse stock split ratio of 1-for-80 indicates potential listing compliance risk